3-(4-Fluorophenyl)-isoxazole-4-carboxylic acid | 334930-07-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4-Fluorophenyl)-isoxazole-4-carboxylic acid
• 英文别名: 3-(4-fluoro-phenyl)-isoxazole-4-carboxylic acid；3-(4-fluorophenyl)isoxazole-4-carboxylic acid；3-(4-fluorophenyl)-1,2-oxazole-4-carboxylic acid
• CAS: 334930-07-3
• 化学式: C₁₀H₆FNO₃
• 分子量: 207.161
• InChiKey: XXDHPFKMYSLBDJ-UHFFFAOYSA-N

物化性质

• 沸点：
  368.3±27.0 °C(Predicted)
• 密度：
  1.404±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.3
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  3-(4-Fluorophenyl)-isoxazole-4-carboxylic acid 在 氯化亚砜 作用下， 反应 1.0h， 生成 3-(4-fluorophenyl)-isoxazole-4-carbonyl chloride
  参考文献：
  名称：

  Isoxazolecarboxamide derivatives

  摘要：

  该发明涉及新型N-(取代苯基)-N′-[ω-(3-取代苯基-4-异噁唑甲酰胺)烷基]哌嗪，它们的N-氧化物以及其药用可接受的盐。这些化合物具有增强的α1-肾上腺素受体选择性和降低血压活性较低。这些化合物在治疗下尿路梗阻综合征，包括良性前列腺增生（BPH），以及治疗下尿路症状（LUTS）和神经源性下尿路功能障碍（NLUTD）等疾病方面具有用途。

  公开号：

  US06365591B1
• 作为产物：
  描述：

  4-fluoro-N-hydroxybenzimidoyl chloride 在 盐酸 、 溶剂黄146 、 三乙胺 作用下， 以 乙醚 为溶剂， 反应 72.75h， 生成 3-(4-Fluorophenyl)-isoxazole-4-carboxylic acid
  参考文献：
  名称：

  Synthesis and Herbicidal Activity of 3-Aryl-5-(haloalkyl)-4-isoxazolecarboxamides and Their Derivatives

  摘要：

  A series of unique 3-aryl-5-(haloalkyl)-4-isoxazolecarboxamides have been prepared which exhibit, in both greenhouse and field studies, significant preemergent and postemergent herbicidal activity in the grams per hectare range against broadleaf and narrowleaf weeds. The key step in the formation of the fully substituted isoxazole ring 2 is 1,3 dipolar cycloaddition of a haloalkyl-substituted acetylenic ester and a nitrile oxide intermediate. The 3-aryl-5-(halo alkyl)-4-isoxazolecarboxylate esters 2 are converted to isoxazole-4-carboxamide herbicides 5 and 6, secondary amides 7, and amino acid derivatives 8. Greatest activity was observed with compounds having a combination of three substituents: a substituted phenyl ring in the 3-position, a primary or secondary carboxamide in the 4-position, and a difluorochloromethyl group in the, 5-position of the isoxazole ring.

  DOI：

  10.1021/jf00049a040

文献信息

• ISOXAZOLE-PYRIDINE DERIVATIVES
  申请人：Buettelmann Bernd

  公开号：US20090143371A1

  公开（公告）日：2009-06-04

  The present invention is concerned with isoxazole-pyridine derivatives of formula I wherein X, R 1 to R 6 are as described herein. The compounds are active on the GABA A α5 receptor binding site and useful for the treatment of cognitive disorders, such as Alzheimer's disease.

  本发明涉及式I的异恶唑-吡啶衍生物 其中X，R1至R6如本文所述。这些化合物对GABA A α5受体结合位点具有活性，并可用于治疗认知障碍，如阿尔茨海默病。
• ISOXAZOLO-PYRIDAZINE DERIVATIVES
  申请人：Buettelmann Bernd

  公开号：US20090143385A1

  公开（公告）日：2009-06-04

  The invention relates to isoxazolo-pyridazine compounds, in particular those of formula I as described above and to a pharmaceutically acceptable salts thereof, having affinity and selectivity for the GABA A α5 receptor binding site, their manufacture, pharmaceutical compositions containing them and their use as cognitive enhancers or for the treatment of cognitive disorders like Alzheimer's disease.

  这项发明涉及异氧唑吡啶嗪化合物，特别是如上所述的式I化合物及其药用盐，具有亲和力和选择性结合到GABA A α5受体结合位点，其制备方法，含有它们的药物组合物以及它们作为认知增强剂或用于治疗认知障碍如阿尔茨海默病。
• ISOXAZOLO-PYRIDINE DERIVATIVES
  申请人：HOFFMANN-LA ROCHE INC.

  公开号：US20130274468A1

  公开（公告）日：2013-10-17

  The present invention is concerned with isoxazole-pyridine derivatives of formula I wherein X, R 1 to R 6 are as described herein. The compounds are active on the GABA A α5 receptor binding site and useful for the treatment of cognitive disorders, such as Alzheimer's disease.

  本发明涉及公式I中的异恶唑-吡啶衍生物，其中X，R1至R6如此描述。这些化合物在GABA A α5受体结合位点上活性，并且用于治疗认知障碍，例如阿尔茨海默病。
• Isoxazolo-pyrazine derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US07902201B2

  公开（公告）日：2011-03-08

  The invention relates to isoxazolo-pyrazine derivatives and their pharmaceutically acceptable salts having affinity and selectivity for the GABA A α5 receptor binding site, their manufacture, and pharmaceutical compositions containing them. The compounds of the present invention are inverse agonists of GABAAα5. The invention also relates to methods for enhancing cognition and for treating cognitive disorders like Alzheimer's disease.

  本发明涉及异噁唑-吡嗪衍生物及其药学上可接受的盐，具有亲和力和选择性，可与GABA A α5受体结合位点结合，其制造和包含它们的制药组合物。本发明的化合物是GABAAα5的反向激动剂。本发明还涉及增强认知和治疗认知障碍如阿尔茨海默病的方法。
• ISOXAZOLO-PYRAZINE DERIVATIVES
  申请人：Buettelmann Bernd

  公开号：US20100256154A1

  公开（公告）日：2010-10-07

  The invention relates to isoxazolo-pyrazine derivatives and their pharmaceutically acceptable salts having affinity and selectivity for the GABA A α5 receptor binding site, their manufacture, and pharmaceutical compositions containing them. The invention also relates to methods for enhancing cognition and for treating cognitive disorders like Alzheimer's disease.

  本发明涉及异噁唑吡嗪衍生物及其药学上可接受的盐，具有亲和力和选择性结合于GABA A α5受体结合位点，其制备方法以及含有它们的制药组合物。本发明还涉及增强认知能力和治疗认知障碍如阿尔茨海默病的方法。